Exhibit 99.1
FOR IMMEDIATE RELEASE
| Contact: | Adam C. Derbyshire | Mike Freeman | ||
| Senior Vice President and | Executive Director, Investor Relations and | |||
| Chief Financial Officer | Corporate Communications | |||
| 919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT CIBC
WORLD MARKETS BIOTECHNOLOGY AND SPECIALTY
PHARMACEUTICAL CONFERENCE
RALEIGH, NC, April 21, 2004 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceutical Conference in New York, NY on Wednesday, April 28 at 3:15 p.m. ET.
Interested parties can access a live audio web cast of the presentation athttp://www.salix.com. A replay of the presentation will be available beginning at 6:00 p.m. ET, Wednesday, April 28 and will be available through Tuesday, May 4.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s 100-member gastroenterology specialty sales and marketing team. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP.”
For more information please contact the Company at 919-862-1000 or visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.
